Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.71 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197968 | 0.87 | LMNA (0.61) | MPOGPR84DRD2DRD3DRD4 | |
| SCHEMBL22584707 | 0.84 | GPR84 (0.58) | MPOGPR84DRD2DRD3DRD4 | |
| SCHEMBL5197105 | 0.84 | DRD2 (0.77) | MPOHTR6GPR84DRD2DRD3 | |
| SCHEMBL947562 | 0.83 | MPO (0.71) | MPOHTR6GPR84DRD2DRD3 | |
| SCHEMBL19252842 | 0.83 | MPO (0.71) | MPOHTR6DRD2DRD3DRD4 | |
| SCHEMBL13499605 | 0.83 | MPO (1.00) | MPOHTR6GPR84DRD2DRD3 | |
| SCHEMBL947201 | 0.81 | HTR1A (0.69) | MPOHTR6GPR84DRD2DRD3 | |
| SCHEMBL948662 | 0.80 | HTR6 (1.00) | MPOHTR6DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL28260331 | 0.78 | HTR6 (0.97) | MPOHTR6DRD2DRD3DRD4 | |
| SCHEMBL945607 | 0.78 | MPO (0.64) | MPOHTR6ALDH1A1BCHECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | ENHANCEDBIO, INC. (KR) | 2020-10-29 | — | — | US | disclosed |
| CN-1720225-B | N-arylsulfonyl-3-substituted indoles having 5-hydroxytryptamine receptor affinity, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LTD | 2011-05-18 | — | — | CN | disclosed |
| US-7875605-B2 | 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-25 | — | — | US | disclosed |
| CN-101544592-A | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LTD (IN) | 2009-09-30 | — | — | CN | disclosed |
| EP-1581492-B1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2008-07-16 | — | — | EP | disclosed |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-10-05 | — | — | US | disclosed |
| CN-1720225-A | N-arylsulfonyl-3-substituted indoles having 5-hydroxytryptamine receptor affinity, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LTD (IN) | 2006-01-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | HTR3A, HTR3C, HTR2C | MPO 4766/4885HTR6 12/4885GPR84 720/4885 |
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | NEDD4, PFDN1, PF4 | MPO 4733/4885HTR6 4165/4885GPR84 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.